Figure 1.

Adjusted mean change from baseline in SF-36 PCS (a) and MCS (b) scores over 52 weeks (ITT population, LOCF). *P < 0.001 for CZP vs PBO by ANCOVA (LOCF imputation). ANCOVA = analysis of covariance; CZP = certolizumab pegol; ITT = intent to treat; LOCF = last observation carried forward; MCID = minimal clinically important difference; MCS = mental component summary; MTX = methotrexate; PBO = placebo; PCS = physical component summary; SF-36 = short-form 36-item health survey.

Strand et al. Arthritis Research & Therapy 2009 11:R170   doi:10.1186/ar2859
Download authors' original image